Jan Kajstura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jan Kajstura has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Annarosa Leri
Cardiovascular Research Institute, Department of Medicine, New York Medical College, Valhalla, New York
4 shared publicationsPiero Anversa
Cardiovascular Research Institute, Department of Medicine, New York Medical College, Valhalla, New York
4 shared publicationsBernardo Nadal-Ginard
From the Cardiovascular Research Institute (J.K., M.R., B.W., S.C., T.H., C.B., D.N., E.Z., M.B., B.N.-G., D.T., A.N., F.Q., K.U., A.L., P.A.), Department of Medicine, New York Medical College, Valhalla; and Department of Physiology and Functional Genomics (H.K.), University of Florida Gainesville
2 shared publicationsClaudia Bearzi
Cardiovascular Research Institute, Department of Medicine, New York Medical College, Valhalla, New York
2 shared publicationsKonrad Urbanek
Cardiovascular Research Institute, Department of Medicine, New York Medical College, Valhalla, New York
2 shared publicationsMarcello Rota
Cardiovascular Research Institute, Department of Medicine, New York Medical College, Valhalla, New York
2 shared publications
Latest Publications
- 1 November 2006
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 8 (11-12) , 2125-2141
The Telomere–Telomerase Axis and the Heart
The preservation of myocyte number and cardiac mass throughout life is dependent on the balance between cell death and cell division. Rapidly emerging evidence indicates that new myocytes can be formed through the activation and differentiation of resident cardiac progenitor cells. The critical issue is the identification of mechanisms that define the aging of cardiac progenitor cells and, ultimately, their inability to replace dying myocytes. The most reliable marker of cellular senescence is the modification of the telomere–telomerase axis, together with the expression of the cell cycle inhibitors p16INK4a and p53. Cellular senescence is characterized by biochemical events that occur within the cell. In this regard, one of the most relevant processes is represented by repeated oxidative stress that may evolve into the activation of the cell death program or result in the development of a senescent phenotype. Thus, the modulation of telomerase activity and the control of telomeric length, together with the attenuation of the formation of reactive oxygen species, may represent important therapeutic tools in regenerative medicine and in prevention of aging and diabetic cardiomyopathies.
- 1 November 2006
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 8 (11-12) , 2125-2141
The Telomere–Telomerase Axis and the Heart
The preservation of myocyte number and cardiac mass throughout life is dependent on the balance between cell death and cell division. Rapidly emerging evidence indicates that new myocytes can be formed through the activation and differentiation of resident cardiac progenitor cells. The critical issue is the identification of mechanisms that define the aging of cardiac progenitor cells and, ultimately, their inability to replace dying myocytes. The most reliable marker of cellular senescence is the modification of the telomere–telomerase axis, together with the expression of the cell cycle inhibitors p16INK4a and p53. Cellular senescence is characterized by biochemical events that occur within the cell. In this regard, one of the most relevant processes is represented by repeated oxidative stress that may evolve into the activation of the cell death program or result in the development of a senescent phenotype. Thus, the modulation of telomerase activity and the control of telomeric length, together with the attenuation of the formation of reactive oxygen species, may represent important therapeutic tools in regenerative medicine and in prevention of aging and diabetic cardiomyopathies.
- 7 January 2005
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 96 (1) , 127-137
Bone Marrow Cells Differentiate in Cardiac Cell Lineages After Infarction Independently of Cell Fusion
Recent studies in mice have challenged the ability of bone marrow cells (BMCs) to differentiate into myocytes and coronary vessels. The claim has also been made that BMCs acquire a cell phenotype different from the blood lineages only by fusing with resident cells. Technical problems exist in the induction of myocardial infarction and the successful injection of BMCs in the mouse heart. Similarly, the accurate analysis of the cell populations implicated in the regeneration of the dead tissue is complex and these factors together may account for the negative findings. In this study, we have implemented a simple protocol that can easily be reproduced and have reevaluated whether injection of BMCs restores the infarcted myocardium in mice and whether cell fusion is involved in tissue reconstitution. For this purpose, c-kit–positive BMCs were obtained from male transgenic mice expressing enhanced green fluorescence protein (EGFP). EGFP and the Y-chromosome were used as markers of the progeny of the transplanted cells in the recipient heart. By this approach, we have demonstrated that BMCs, when properly administrated in the infarcted heart, efficiently differentiate into myocytes and coronary vessels with no detectable differentiation into hemopoietic lineages. However, BMCs have no apparent paracrine effect on the growth behavior of the surviving myocardium. Within the infarct, in 10 days, nearly 4.5 million biochemically and morphologically differentiated myocytes together with coronary arterioles and capillary structures were generated independently of cell fusion. In conclusion, BMCs adopt the cardiac cell lineages and have an important therapeutic impact on ischemic heart failure.
- 7 January 2005
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 96 (1) , 127-137
Bone Marrow Cells Differentiate in Cardiac Cell Lineages After Infarction Independently of Cell Fusion
Recent studies in mice have challenged the ability of bone marrow cells (BMCs) to differentiate into myocytes and coronary vessels. The claim has also been made that BMCs acquire a cell phenotype different from the blood lineages only by fusing with resident cells. Technical problems exist in the induction of myocardial infarction and the successful injection of BMCs in the mouse heart. Similarly, the accurate analysis of the cell populations implicated in the regeneration of the dead tissue is complex and these factors together may account for the negative findings. In this study, we have implemented a simple protocol that can easily be reproduced and have reevaluated whether injection of BMCs restores the infarcted myocardium in mice and whether cell fusion is involved in tissue reconstitution. For this purpose, c-kit–positive BMCs were obtained from male transgenic mice expressing enhanced green fluorescence protein (EGFP). EGFP and the Y-chromosome were used as markers of the progeny of the transplanted cells in the recipient heart. By this approach, we have demonstrated that BMCs, when properly administrated in the infarcted heart, efficiently differentiate into myocytes and coronary vessels with no detectable differentiation into hemopoietic lineages. However, BMCs have no apparent paracrine effect on the growth behavior of the surviving myocardium. Within the infarct, in 10 days, nearly 4.5 million biochemically and morphologically differentiated myocytes together with coronary arterioles and capillary structures were generated independently of cell fusion. In conclusion, BMCs adopt the cardiac cell lineages and have an important therapeutic impact on ischemic heart failure.
- 1 June 2001
- Published by American Diabetes Association in Diabetes
- Vol. 50 (6) , 1414-1424
IGF-1 Overexpression Inhibits the Development of Diabetic Cardiomyopathy and Angiotensin II–Mediated Oxidative Stress
Stimulation of the local renin-angiotensin system and apoptosis characterize the diabetic heart. Because IGF-1 reduces angiotensin (Ang) II and apoptosis, we tested whether streptozotocin-induced diabetic cardiomyopathy was attenuated in IGF-1 transgenic mice (TGM). Diabetes progressively depressed ventricular performance in wild-type mice (WTM) but had no hemodynamic effect on TGM. Myocyte apoptosis measured at 7 and 30 days after the onset of diabetes was twofold higher in WTM than in TGM. Myocyte necrosis was apparent only at 30 days and was more severe in WTM. Diabetic nontransgenic mice lost 24% of their ventricular myocytes and showed a 28% myocyte hypertrophy; both phenomena were prevented by IGF-1. In diabetic WTM, p53 was increased in myocytes, and this activation of p53 was characterized by upregulation of Bax, angiotensinogen, Ang type 1 (AT1) receptors, and Ang II. IGF-1 overexpression decreased these biochemical responses. In vivo accumulation of the reactive O2 product nitrotyrosine and the in vitro formation of H2O2-˙OH in myocytes were higher in diabetic WTM than TGM. Apoptosis in vitro was detected in myocytes exhibiting high H2O2-˙OH fluorescence, and apoptosis in vivo was linked to the presence of nitrotyrosine. H2O2-˙OH generation and myocyte apoptosis in vitro were inhibited by the AT1 blocker losartan and the O2 scavenger Tiron. In conclusion, IGF-1 interferes with the development of diabetic myopathy by attenuating p53 function and Ang II production and thus AT1 activation. This latter event might be responsible for the decrease in oxidative stress and myocyte death by IGF-1.
- 1 June 2001
- Published by American Diabetes Association in Diabetes
- Vol. 50 (6) , 1414-1424
IGF-1 Overexpression Inhibits the Development of Diabetic Cardiomyopathy and Angiotensin II–Mediated Oxidative Stress
Stimulation of the local renin-angiotensin system and apoptosis characterize the diabetic heart. Because IGF-1 reduces angiotensin (Ang) II and apoptosis, we tested whether streptozotocin-induced diabetic cardiomyopathy was attenuated in IGF-1 transgenic mice (TGM). Diabetes progressively depressed ventricular performance in wild-type mice (WTM) but had no hemodynamic effect on TGM. Myocyte apoptosis measured at 7 and 30 days after the onset of diabetes was twofold higher in WTM than in TGM. Myocyte necrosis was apparent only at 30 days and was more severe in WTM. Diabetic nontransgenic mice lost 24% of their ventricular myocytes and showed a 28% myocyte hypertrophy; both phenomena were prevented by IGF-1. In diabetic WTM, p53 was increased in myocytes, and this activation of p53 was characterized by upregulation of Bax, angiotensinogen, Ang type 1 (AT1) receptors, and Ang II. IGF-1 overexpression decreased these biochemical responses. In vivo accumulation of the reactive O2 product nitrotyrosine and the in vitro formation of H2O2-˙OH in myocytes were higher in diabetic WTM than TGM. Apoptosis in vitro was detected in myocytes exhibiting high H2O2-˙OH fluorescence, and apoptosis in vivo was linked to the presence of nitrotyrosine. H2O2-˙OH generation and myocyte apoptosis in vitro were inhibited by the AT1 blocker losartan and the O2 scavenger Tiron. In conclusion, IGF-1 interferes with the development of diabetic myopathy by attenuating p53 function and Ang II production and thus AT1 activation. This latter event might be responsible for the decrease in oxidative stress and myocyte death by IGF-1.
- 1 March 2000
- Published by Elsevier in The American Journal of Pathology
- Vol. 156 (3) , 813-819
Telomere Shortening Is an in Vivo Marker of Myocyte Replication and Aging
- 1 March 2000
- Published by Elsevier in The American Journal of Pathology
- Vol. 156 (3) , 813-819
Telomere Shortening Is an in Vivo Marker of Myocyte Replication and Aging